MetLife Investment Management
AVBP icon

MetLife Investment Management’s ArriVent BioPharma AVBP Stock Holding History

MetLife Investment Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$777K Buy
22,360
+5,036
+29% +$149K ﹤0.01% 1654
2026
Q1 		$400K Buy
17,324
+667
+4% +$15.1K ﹤0.01% 1859
2025
Q4 		$335K Sell
16,657
-453
-3% -$9.43K ﹤0.01% 1994
2025
Q3 		$316K Hold
17,110
– – ﹤0.01% 2052
2025
Q2 		$372K Hold
17,110
– – ﹤0.01% 1817
2025
Q1 		$316K Sell
17,110
-350
-2% -$8.56K ﹤0.01% 1941
2024
Q4 		$465K Buy
17,460
+1,110
+7% +$31.9K ﹤0.01% 1843
2024
Q3 		$384K Buy
16,350
+10,269
+169% +$233K ﹤0.01% 1924
2024
Q2 		$113K Buy
6,081
+567
+10% +$10.1K ﹤0.01% 2550
2024
Q1 		$98.5K Buy
+5,514
New +$111K ﹤0.01% 2547

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MetLife Investment Management's AVBP Position: Q2 2026 in Review

MetLife Investment Management increased its ArriVent BioPharma (AVBP) stake by 29% in Q2 2026, buying an estimated $149K and bringing the position to 22,360 shares worth $777K. The position accounts for ﹤0.01% of the portfolio, ranked #1654.

MetLife Investment Management first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • MetLife Investment Management held 22,360 shares of ArriVent BioPharma worth $777K as of Q2 2026.
  • MetLife Investment Management bought 5,036 ArriVent BioPharma shares in Q2 2026, an estimated $149K.
  • ArriVent BioPharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1654 holding.
  • MetLife Investment Management first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.